IMMUDIAB Research Group

Autoreactive T cell

Combined Immunotherapy and Islet Regeneration to Cure Type 1 Diabetes

The aim of the project is to reverse autoimmunity in patients with recent onset and established type 1 diabetes (T1D) and to restore natural normoglycemia. This is to be achieved through an integrative and combinatorial treatment that modulates the immune system to a minimal degree and that needs only a minimal intervention for beta-cell restoration. Minimal intervention means that, once autoimmunity is reversed, regeneration is to be activated in order to recreate beta-cell mass and restore insulin secretion. The particular advantage of this approach is to control autoimmunity site-specifically rather than systemically and to induce the regenerative potential of the endocrine pancreas. The project is scheduled for a period of 5 years. The consortium consists of 4 academic centers and 1 industry partner.

If you are interested in this project and if you would like to learn more about the details, do not hesitate to contact us by mail at immudiab(at)